A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
Phase of Trial: Phase III
Latest Information Update: 31 May 2018
At a glance
- Drugs Budesonide (Primary)
- Indications Eosinophilic oesophagitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Shire
- 31 Aug 2018 Biomarkers information updated
- 06 Oct 2017 Status changed from not yet recruiting to recruiting.
- 19 Sep 2017 Planned initiation date changed from 22 Sep 2017 to 2 Oct 2017.